Sally Mravcak, MD
Family Medicine · Jersey City, NJNPI 1811009657
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,270 of the $64,499 with a category attached, or 84.1%. Gilead accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. Among family medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $724.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$64K
- Exact Sciences$25
- Novartis$16
What the payments were for
- Speaking & faculty fees$54,27084%
- Travel & lodging$8,56613%
- Food & beverage$1,6633%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 87 | $64,458 |
| Exact Sciences | 1 | $25 |
| Novartis | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$64,499 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 45 | $51,173 |
| EliquisApixaban | 21 | $30,507 |
| OzempicSemaglutide | 22 | $28,769 |
| FarxigaDapagliflozin Propanediol | 21 | $21,189 |
| MounjaroTirzepatide | 12 | $13,380 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $10,387 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 32 | $9,804 |
| JanuviaSitagliptin Phosphate | 13 | $8,647 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 21 | $4,656 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,628 |
| Atorvastatin Calcium | 262 | $2,841 |
| Rosuvastatin Calcium | 96 | $2,733 |
| Amlodipine Besylate | 175 | $1,173 |
| Valsartan | 37 | $1,125 |
| SynthroidLevothyroxine Sodium | 20 | $1,062 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Jersey City
- John FritzJersey City$22K
- Rupal BhingradiaJersey City$13K
- Mikhail VarshavskiChatham$1.4M
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
- Jennifer CaudleSewell$226K
- Jeffrey LevineNew Brunswick$195K
- Jennifer AmicoNew Brunswick$159K
- Dena LacaraFairfield$122K
- Gaurang BrahmbhattHoboken$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.